Thanks to a new early access deal and the intercontinental oncology effort Project Orbis, England will be the first European country where patients with later-stage p...

Horizon Therapeutics has teamed up with Xeris Biopharma to create an ultra-concentrated, ready-to-use, subcutaneous formulation of teprotumumab, handing over an upfro...

Genentech has kicked off a phase 2a clinical trial to optimize subretinal surgical delivery of OpRegen, a cell therapy that is in development as a treatment for the e...

Three months after gaining its first worldwide approval, from Indonesia, for its dengue fever vaccine, Takeda is progressing toward a blessing from the FDA. The Japa...

Johnson & Johnson’s esketamine nasal spray continues to build a body of evidence showing it can go toe-to-toe with tough-to-treat depression. Wednesday, J&...

Teva Pharmaceutical and AbbVie’s Allergan are finally on the verge of putting thousands of opioid lawsuits to bed. The companies this week locked in a combined $6.6 ...

Trilogy Writing & Consulting, a company specialised in regulatory writing, announced that one of its Senior Partners, Julia Forjanic Klapproth, was honored with t...

Amid an organizational reshuffling, an 8,000-person layoff round and a spinoff of generics giant Sandoz, Novartis CEO Vas Narasimhan, M.D., is still not done with his...

Recently acquainted under the banner of investment firm Altaris, two CDMO veterans are gearing up to wed their decades-old drug delivery businesses. Kindeva Dr...

The hits just keep on coming for India manufacturing giant Lupin as it continues to run afoul of the FDA. In a regulatory filing late last month with the Bombay Stoc...